{
    "clinical_study": {
        "@rank": "33638", 
        "arm_group": {
            "arm_group_label": "Azilsartan at a dose of 20 to 40 mg, orally, once daily", 
            "description": "Azilsartan tablets"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of azilsartan tablets (Azilva Tablets)\n      in patients with hypertension complicated by diabetes mellitus whose blood pressure cannot\n      be sufficiently reduced by monotherapy with angiotensin II receptor blockers (ARBs) other\n      than azilsartan, in routine clinical practice"
        }, 
        "brief_title": "Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance \"Hypertension Complicated by Diabetes \"", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This study was designed to evaluate the efficacy of azilsartan tablets (Azilva Tablets) in\n      patients with hypertension complicated by diabetes mellitus whose blood pressure cannot be\n      sufficiently reduced by monotherapy with ARBs, other than azilsartan, in daily medical\n      practice.\n\n      Subject enrollment will be started on April 1, 2014. The usual dosage for adults is 20 mg of\n      azilsartan administered orally once daily. The dose can be adjusted according to the\n      patient's age and condition. The maximum daily dose is 40 mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with hypertension who meet all the following criteria will be enrolled:\n\n               1. Patients who has complications of diabetes mellitus\n\n               2. Patients who is on monotherapy with ARBs (other than azilsartan) as\n                  antihypertensive treatment (Patients who have continued monotherapy with the\n                  same ARB product for at least 8 weeks at the time of Step-1* of subject\n                  enrollment and will continue such treatment until the first administration of\n                  Azilva Tablets)\n\n               3. Patients who has a systolic blood pressure of \u2265 130 mmHg and/or diastolic blood\n                  pressure of 80 \u2265 mmHg at the examination performed at the medical institution\n\n               4. Patients who is an outpatient\n\n               5. Patient who keeps a regular lifestyle and whose usual waking time is between 4\n                  a.m. and 9:30 a.m.\n\n                    -  For this surveillance, subject enrollment will be performed in two divided\n                       steps: Step-1 (at hospital visit before prescription of Azilva Tablets) and\n                       Step-2 (at the time of prescription of Azilva Tablets).\n\n        Exclusion Criteria:\n\n          -  Patients with contraindications to azilsartan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hypertension"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100319", 
            "org_study_id": "279-012"
        }, 
        "intervention": {
            "arm_group_label": "Azilsartan at a dose of 20 to 40 mg, orally, once daily", 
            "description": "Azilsartan tablets", 
            "intervention_name": "Azilsartan", 
            "intervention_type": "Drug", 
            "other_name": "Azilva Tablets"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Azilva Tablets Special Drug Use Surveillance \"Hypertension Complicated by Diabetes \"", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+1-800-778-2860"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Summary statistics of measured values and respective changes from baseline will be calculated at each time point in daily medical practice", 
            "measure": "Changes from baseline in blood pressure measured at the medical institution and at home", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100319"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Summary statistics of measured values and respective changes from baseline will be calculated at each test time point in daily medical practice.", 
                "measure": "Changes from baseline in pulse rate measured at the medical institution, HbA1c (National Glycohemoglobin Standardization Program [NGSP] value), and urinary albumin level (creatinine-adjusted value)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks"
            }, 
            {
                "description": "Summary statistics of measured values and respective changes from baseline will be calculated at each test time point in daily medical practice.", 
                "measure": "Changes from baseline in HbA1c (National Glycohemoglobin Standardization Program [NGSP] value) at the medical institution", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks"
            }, 
            {
                "description": "Summary statistics of measured values and respective changes from baseline will be calculated at each test time point in daily medical practice", 
                "measure": "Changes from baseline in urinary albumin level (creatinine-adjusted value) at the medical institution", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks"
            }, 
            {
                "description": "The frequency of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of azilsartan, whether or not it was considered related to the treatment.", 
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "For 24 weeks"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}